High-dose chemotherapy for rhabdomyosarcoma: where do we go from here

J Pediatr Hematol Oncol. Jun-Jul 2001;23(5):266-7. doi: 10.1097/00043426-200106000-00005.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Diseases / chemically induced
  • Bone Marrow Diseases / therapy
  • Child
  • Forecasting
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Multicenter Studies as Topic
  • Pilot Projects
  • Randomized Controlled Trials as Topic
  • Rhabdomyosarcoma / drug therapy*
  • Rhabdomyosarcoma / mortality
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / mortality
  • Survival Rate
  • Treatment Outcome